InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Tzianabos Arthur, Chairman & CEO. Insider active across 4 companies, notably Homology Medicines, Inc.. Aggregated, 8 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €14k. Activity tracked since 9 January 2023. The latest transaction was disclosed on 10 March 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Tzianabos Arthur
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
3,955 shares@ US$8.3330.5% of flowCommon StockSEC:0001586226-26-000002:0
1,095 sharesCommon StockSEC:0000950170-24-096986:0
14,280 sharesCommon StockSEC:0000950170-24-015944:0
31,739 shares@ US$2.19100.0% of flowCommon StockSEC:0001415889-24-003897:0
10,616 shares@ US$1.3905100.0% of flowCommon StockSEC:0000899243-23-001574:0
13,860 sharesCommon StockSEC:0000899243-23-000632:0
26,930 sharesCommon StockSEC:0001104659-22-124141:0
13,860 sharesCommon StockSEC:0000899243-22-001743:0
8 of 8 declarations
About Tzianabos Arthur
Arthur Tzianabos is the Chief Executive Officer of Homology Medicines, Inc. In this role, he leads the company's operations and strategy in the field of gene therapies. His expertise in this sector enables him to drive innovative initiatives to improve treatments offered to patients.
